AstraZeneca’s Wainua trial failure in transthyretin cardiac amyloidosis (ATTR-CM) has shifted scrutiny onto competing RNA-silencing approaches, according to the Stock/analysis coverage. As investors and analysts interpret the miss, Alnylam is responding by defending its “silencer” strategy—positioning its current product Amvuttra and next-generation nucresiran as the more compelling pathway versus stabilizer-only regimens. The debate centers on whether combining mechanisms adds benefit when patients are already treated with stabilizers. Alnylam’s defense suggests it expects differentiation on efficacy, safety, or durability to withstand the market read-through from Wainua’s results. For the RNAi space, the episode highlights how quickly clinical setbacks can ripple across mechanism categories, tightening the evidence bar for next readouts in ATTR-CM and related cardiovascular indications.